ASG 5ME

Drug Profile

ASG 5ME

Alternative Names: AGS-5-ME; ASG-5-ME

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Agensys; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 31 Jul 2013 Discontinued - Phase-I for Gastric cancer in USA (IV)
  • 31 Jul 2013 Discontinued - Phase-I for Pancreatic cancer in USA (IV)
  • 31 Jul 2013 Discontinued - Phase-I for Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top